Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qixian Qingming Granules
- Development stage
- Unknown
- Administration
- Oral
01
Overview
Qixian Qingming Granules (芪仙清鸣颗粒) is a traditional Chinese medicine (TCM) formulation. It is presented as granules for oral administration. The specific composition, mechanism of action, and primary indications are not detailed in the available sources. Based on the naming convention and typical TCM practice, it likely contains Astragalus (黄芪, "Qi") as a principal ingredient and may be used for respiratory or immune-related conditions; however, no direct evidence or official documentation confirming its ingredients or clinical use was found in the provided search results.
- Brand names
- Qixian Qingming Granules
- Other names
- 芪仙清鸣颗粒
02
Targets
BCL-2 (BCL-2 family)CASP3 (Caspase-3)EGFR (Epidermal growth factor receptor)mTOR (Mammalian target of rapamycin kinase)NFKB1 (NF-κB1)CDH1 (Cadherin-1)MAPK3 (Mitogen-activated protein kinase 1)
Beyond the preview
Go deeper on Qixian Qingming Granules.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Qixian Qingming Granules.